NCT07638007Recruiting
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 22 Apr 2026
- Start date
- 21 Nov 2025
- Primary completion date
- 28 Feb 2029
- Lead sponsor
- University of Rochester NCORP Research Base
- NCT number
- NCT07638007
What you commit to
- Study type: Observational
- Planned participants: 400
- From 21 Nov 2025 to the primary completion date, 28 Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants must have no history of cytotoxic chemotherapy, immune checkpoint inhibitor therapy, hormonal therapy, biologic therapy, radiotherapy within the past 5 years. However, permitted treatments include prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
- Participants must have no history of stroke within the past year and no remaining cognitive symptoms from any stroke prior to the past year
- Participants must have no history of head trauma with loss of consciousness within the year prior to consent
- Participants must not be study staff who have previously viewed or administered the objective cognitive function measures (e.g., CANTAB)
Other illness
- Participants must have no history of metastatic cancer, primary brain tumor, or brain irradiation
- Participants must have no history of TKI therapy
- Participants must have no diagnosis of dementia or severe neurodegenerative disease impairing daily functioning
- Participants must have no psychiatric condition that led to hospitalization within the past year
Other
- Participants must not be currently pregnant
- Participants must not be colorblind based on self-report
Who the study is looking for
- TKI RECIPIENTS: Participants must have a diagnosis of CML or CLL
- TKI RECIPIENTS: Participants must be scheduled to receive their first dose of TKI therapy for CML or CLL within 30 days or have received their first dose of TKI therapy for CML or CLL within the previous 30 days
- TKI RECIPIENTS: Participants must be ≥ 18 years of age
- TKI RECIPIENTS: Participants must be able to speak and read English
- TKI RECIPIENTS: Participants must be able to understand and willing to sign an informed consent document
- CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be ≥ 18 years of age
- CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to speak and read English
- CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to understand and willing to sign an informed consent document
- CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Each participant must be matched to a TKI recipient participant based on sex and age ±5 years (i.e., must be no more than 5 years older or younger than the TKI recipient participant)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Rochester NCORP Research Base Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.